is...optimistic for the future of CNS conditions thanks to Anavex Life Sciences.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wasn’t this Parkinson’s trial slated for 14 weeks?
https://www.anavex.com/anavex-life-sciences-reaches-50-enrollment-threshold-in-anavex2-73-parkinsons-disease-dementia-pdd-phase-2-study-ahead-of-schedule/
Aren’t we around the end of that time period? Has unblinding already happened, and would that suggest forthcoming results?
From an earlier poster...
https://anavex.com//wp-content/uploads/Sigma-1-Receptor-Agonists-as-Potential-Treatment-Options.pdf
“Autism spectrum disorders (ASD) occur in up to 2/3 of males and 1/3 of females with Fragile X syndrome (FXS). FXS is the most common form of inherited intellectual disability and the most frequent single gene cause of autism, affecting approximately 1 in 4,000 males and 1 in 6,000 females. In addition to the clinical overlap between FXS and ASD, there is likely a substantial overlap in the molecular pathology of the two disorders. Molecules aimed at targets in these shared pathways are expected to have therapeutic overlap in subsets of individuals with ASD or neurodevelopmental disorders.”
Given the extent to which mitochondrial functionality affects a range of conditions, could studies be done for the various Autism Spectrum Disorders such as Asperger’s? Perhaps following the Fragile X and Angelman studies?
From the FierceBiotech link...
“Statistically speaking, this was bound to happen: Despite the hype and the hope coming from Biogen, 99% of all trials in Alzheimer’s have failed over the past 15 years, and drugs on the market for the memory-wasting disease are limited in their capacity to curb its effects.”
Meanwhile, most patients on Anavex 2-73 are alive and many have stabilized or improved in the last 5 years.
Tick-tock. New CNS champ coming to fruition.
Slowing intracellular bacterial infection is another plus...
https://www.nature.com/articles/s41467-018-06487-5
Searching “GABA” and “cholinergic neurotransmission” yields plenty of related research.
The ball is definitely in Anavex’s court.
E.g.-
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584188/
Reestablishing homeostasis at the cellular level and activating that autophagy is good stuff.
Outstanding.
Top of the Stickies! Post-it!
Thanks George!
Haven’t sold a share since 2014. Continued to accumulate!
Proud to be an INVESTOR.
Dosages are really high compared to 2-73 too!
This study provides Class I evidence that for children/adolescents with RTT, trofinetide was safe, well-tolerated, and demonstrated improvement over placebo at 200 mg/kg bid in functionally important dimensions of RTT.
While 2-73 achieves safe, tolerated results in the 5 mg dosage!
Happy Birthday and plenty of gratitude to ya’! <3
40-400 per share...minimum.
Have an amazing birthday, and many more!
Worth re-reading...
https://www.globenewswire.com/news-release/2019/05/08/1819308/0/en/Rett-Syndrome-Association-of-Australia-and-Anavex-Life-Sciences-Announce-Initiation-of-the-Phase-2-AVATAR-Clinical-Study-in-Patients-with-Rett-Syndrome.html
And here we are almost 5 months later “under a voluntary open label extension protocol”!
Yeah...Thursday/Friday are going to be a couple of days worth remembering in the Rett Syndrome ‘herstory’ books. And that will be a very positive thing for Anavex as well.
GLTA, but especially longs.
Leslie Stahl’s HUSBAND has Parkinson’s...
https://www.brainandlife.org/articles/60-minutes-correspondent-lesley-stahl-says-she-and-her-husband/
Any other company have these results?
Inhaled versus Ingested Medication
If Anavex 2-73 or 3-71 were inhaled, would they be as effective, less effective, or more effective?
Just wondering whether Technosphere could be an option for patients, especially if there are patients who do not possess specific gut flora described in the research.
https://www.mannkindcorp.com/research-development/tech-platforms/dry-powder-formulation/
Disruptive Technology
Kiss those egg-based vaccines goodbye.
Thanks plex.
Development, Marketing, and Distribution question
Any experienced folks here have “typical” costs associated with the post-trial processes necessary for making a new pharmaceutical available?
To have $250M possibly available with the release of positive news would imply that, instead of partnering with a large pharma for their established D, M, and B sections, Anavex would be able to go it alone.
Would $250M be sufficient for such an enterprise?
Viva Cellceutix! (flashback)
So out of all the OM players, IPIX is pushing forward with the positive results. BRAVO!!!
Global Oral Mucositis Drugs Market includes complete profiles of major key players: – Clevexel Pharma SAS , Colby Pharmaceutical Company , Galera Therapeutics Inc , Humanetics Corp , Innovation Pharmaceuticals Inc , Onxeo SA , Oragenics Inc , Otsuka Holdings Co Ltd , Soligenix Inc , Spectrum Pharmaceuticals Inc , Spherium Biomed SL , ,
Will hope for eventual positive outcomes on Kevetrin and Prurisol as well.
Seems as though the partnership is in effect...
https://potstocks.online/2018/10/17/9042/
The BIIB plunge...
I’d say our AVXL is worth well north of $18 billion, but I wonder if Biogen will consider trying to acquire the whole kit and kaboodle, or if Dr. Missling and the board would even allow an outright acquisition?
Good question. I don’t have an answer.
If there is not a release of positive RSV-F results at the JPM Healthcare Conference, then it’ll be a buying opportunity from an intense FUD assault. NVAX’s VLP NanoFlu outcomes put them ahead of current vaccine makers by a remarkable margin (a definite threat to Sanofi’s FluZone HD) and signals a watershed moment in the field of disease prophylaxis.
October presentation for newer investors looking up RSV...
http://novavax.com/presentation.show
Not Worried
Will be nice to see this bad boy run!
CLAY and his short posse can kindly pass through a pug mill for squeezing purposes!
No doubt we’ll see a frenzied burst of algo activity coupled with hit pieces and plenty of FUD players showing up to post filth, but Nano? And a strong possibility of RSV pozzy results means they’ll PAY!
How many short?! 50+ million shares? Time to cover?
Over 2 years ago...
https://www.anavex.com/anavex-compound-to-be-tested-in-biogen-neurological-protection-model/
Talk about keeping things under wraps! That’s a blanket of secrecy worthy of Skunkworks at this point.
IMHO, this is the year the beast is let out of its cage, esp. with 3 trials under way and remyelination confirmation awaiting disclosure.
When will it all gel?
From the Equus asinus twitter account...
Come join my shorting group where all we do is short penny stocks into the ground! Join here: https://t.co/uWPWueN3Bi
— ClayTrader (@ClayTrader25) July 19, 2016
Way to go.
Congrats!
Order filled!
$6,000 available mid-January. No news before then could mean a few more shares.
A very Merry post-Christmas buying opportunity to say the least. ¡Qué suerte!
Buyer’s market!
Never thought I’d have the chance to accumulate more shares at pre-split prices, but here we are!
If the price can stay suppressed into January, it’ll feel like a shopping spree, but looking at the volumes posted yesterday and today, it’s obviously manipulation + some year-end selling. Yippee for year-end bonus timing!
Buying opportunity!
And here I thought I might not be able to add more on the cheap. Love a deal!
(guessing end of year selloffs?)
Sure would be nice to have progress made on this...
Ebola GP Vaccine
Ebola virus (EBOV), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. Multiple strains of EBOV have been identified, the most recent of which, the Makona strain, is associated with a case fatality rate of between 50% and 90%. There are currently no licensed treatments proven to neutralize the virus but a range of blood, immunological and drug therapies are under development. Despite the development of such therapies, current vaccine approaches target either a previous strain of the virus or were initially developed to be delivered by genetic vectors. In contrast, our EBOV glycoprotein vaccine candidate (Ebola GP Vaccine) was developed using the Makona EBOV strain.
In July 2015, we announced data from our Phase 1 clinical trial of our Ebola GP Vaccine in ascending doses, with and without our Matrix-M adjuvant, in 230 healthy adults. Participants received either one or two intramuscular injections with or without adjuvant, or placebo, and immunogenicity was assessed at multiple time points, including days 28 and 35. These Phase 1 data demonstrated that our Ebola GP Vaccine is highly immunogenic, well-tolerated and, in conjunction with our proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing. Although the adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels, the adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units, representing a 500 to 750-fold rise over baseline at day 35. In 2015, we also announced successful data from two separate non-human primate challenge studies of our Ebola GP Vaccine in which, in both cases, the challenge was lethal for the control animal, whereas 100% of the immunized animals were protected.
Thank you for that testimony.
Should be on the front page of newspapers and websites nationwide.
Translates to quick filling and commencement.
Question...
Have there been any updates related to Dr. Robert Lisak and the Wayne State University School of Medicine?
Seems the last news release was:
https://www.anavex.com/new-data-related-to-multiple-sclerosis/
It’s been a year.
Last significant post seems to be from Polarbear77 #134327
Aw yeah...full steam ahead!
“...enrolled the first patient in its Phase 2 double-blind, randomized, placebo-controlled, 14-week safety and efficacy trial of ANAVEX®2-73 for the treatment of Parkinson’s disease dementia (PDD).”
Gladdens the heart!
2019: The Year of Anavex
Guess: Before the end of the year?
“The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials.”
Efficiency is an overlooked factor.
Also, governmental funding for a solution to issues causing billions or trillions in healthcare costs is just common sense.
from the Washington Post Health 202...
“The CDC and the Alzheimer’s Association today are launching a guide for the next five years that outlines strategies for addressing Alzheimer’s disease as a public health crisis. The CDC's Behavioral Risk Factor Surveillance System reports 11 percent of adults ages 45 and up have experienced cognitive decline in the last year, according to a news release, but more than half don't discuss it with a health-care provider. The framework from the CDC and Alzheimer's Association looks to the public health community to help reduce risk, and expand early detection and diagnosis of the Alzheimer's disease, among other strategies.”
FIVE YEARS?
Australia...you know what needs to be done. Do it. We need 2-73 and 3-71 available to as many patients as possible.
Just waiting there in the wings for its spotlight!
KMFC for all the patients.
Question: Is Anavex 3-71 supposed to be more potent than Anavex 2-73?